Last reviewed · How we verify
Rituximab for Patients with B-Cell Malignancies
Rituximab for Patients with B-Cell Malignancies is a Small molecule drug developed by M.D. Anderson Cancer Center. It is currently in Phase 1 development. Also known as: Rituxan.
At a glance
| Generic name | Rituximab for Patients with B-Cell Malignancies |
|---|---|
| Also known as | Rituxan |
| Sponsor | M.D. Anderson Cancer Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Stomatitis
- Diarrhoea
- Nausea
- Neutropenia
- Fatigue
- Pyrexia
- Cough
- Oedema peripheral
- Rash
- Anaemia
- Thrombocytopenia
- Mouth ulceration
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia (PHASE1, PHASE2)
- Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell Lymphoma (PHASE1)
- Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas (PHASE2, PHASE3)
- Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma (PHASE1)
- Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma (PHASE1)
- Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma (PHASE2)
- LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rituximab for Patients with B-Cell Malignancies CI brief — competitive landscape report
- Rituximab for Patients with B-Cell Malignancies updates RSS · CI watch RSS
- M.D. Anderson Cancer Center portfolio CI
Frequently asked questions about Rituximab for Patients with B-Cell Malignancies
What is Rituximab for Patients with B-Cell Malignancies?
Rituximab for Patients with B-Cell Malignancies is a Small molecule drug developed by M.D. Anderson Cancer Center.
Who makes Rituximab for Patients with B-Cell Malignancies?
Rituximab for Patients with B-Cell Malignancies is developed by M.D. Anderson Cancer Center (see full M.D. Anderson Cancer Center pipeline at /company/m-d-anderson-cancer-center).
Is Rituximab for Patients with B-Cell Malignancies also known as anything else?
Rituximab for Patients with B-Cell Malignancies is also known as Rituxan.
What development phase is Rituximab for Patients with B-Cell Malignancies in?
Rituximab for Patients with B-Cell Malignancies is in Phase 1.
What are the side effects of Rituximab for Patients with B-Cell Malignancies?
Common side effects of Rituximab for Patients with B-Cell Malignancies include Stomatitis, Diarrhoea, Nausea, Neutropenia, Fatigue, Pyrexia.
Related
- Manufacturer: M.D. Anderson Cancer Center — full pipeline
- Also known as: Rituxan
- Compare: Rituximab for Patients with B-Cell Malignancies vs similar drugs
- Pricing: Rituximab for Patients with B-Cell Malignancies cost, discount & access